Outlook Therapeutics gets FDA review acceptance for wet AMD treatment

Stock Information for Outlook Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Outlook Therapeutics Inc.

Outlook Therapeutics to Present at the Piper Sandler 37th Annual Healthcare Conference
Outlook Therapeutics Announces Acceptance of Biologics License Application by U.S. FDA for ONS-5010 as a Treatment for Wet AMD
Outlook Therapeutics Re-Submits Biologics License Application for ONS-5010
Outlook Therapeutics Provides Update on Type A Meeting with FDA
Outlook Therapeutics to Present at the 2025 EURETINA Innovation Spotlight (EIS)
Outlook Therapeutics Requests Type A Meeting with FDA
Outlook Therapeutics Provides Regulatory Update on U.S. Food and Drug Administration Review of ONS-5010/LYTENAVA(TM) (bevacizumab-vikg) for the Treatment of Wet AMD
Outlook Therapeutics Reports Financial Results for Third Quarter Fiscal Year 2025 and Provides Corporate Update

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.